A Case of Psoriasis in an HIV Positive Male

Merchant, Omar F

doi:10.23937/2378-3656/1410052

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unresolved cases have been reportedly treated with methotrexate, cyclosporine, tumor necrosis factor inhibitors, and hydroxyurea [ 6 ]. Additionally, biologics targeting interleukin-23 (IL-23) may be a favorable option in HIV since they are less likely to interact with opportunistic infections [ 9 ]. These immunosuppressants require close monitoring of CD4+ count, opportunistic infections, and malignancies [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

Acute HIV Infection Presenting With Diffuse Plaque Psoriasis Treated With Highly Active Antiretroviral Therapy

Bressler¹,

Pathak²,

Rotblat³

et al. 2021

Cureus

View full text Add to dashboard Cite

Cutaneous diseases such as psoriasis are often the first disease manifestations in HIV+ patients, with greater severity corresponding to a weaker immune system. Despite its prevalence, literature and placebo-controlled studies on the recognition of HIV as a cause of psoriasis are lacking, causing challenges to arise in its treatment. In this article, we illustrate a case of an HIV+ patient whose psoriasis drastically improved after the initiation of highly active antiretroviral therapy (HAART) consisting of bictegravir, emtricitabine, and tenofovir alafenamide. While it is unclear which combination of antiretrovirals is optimal for controlling psoriasis in HIV+ patients, prompt initiation of HAART can significantly improve immune status and psoriasis in HIV+ patients.

show abstract

Section: Discussionmentioning

confidence: 99%